ReviewFrontiers in aging neuroscience2013
Roles of vascular and metabolic components in cognitive dysfunction of Alzheimer disease: short- and long-term modification by non-genetic risk factors.
Review in Frontiers in aging neuroscience, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Association Between Interleukin-1A, Interleukin-1B, and Bridging integrator 1 Polymorphisms and Alzheimer's Disease: a standard and Cumulative Meta-analysis.Molecular neurobiology · 2017Pooled it
- Transcranial near infrared therapy reprograms metabolism to rescue sleep and place cell functionality.iScience · 2025Article
- Point-of-care optical spectroscopy platform and ratio-metric algorithms for rapid and systematic functional characterization of biological modelsJournal of biomedical optics · 2024Article
- The clinical features and potential mechanisms of cognitive disorders in peripheral autoimmune and inflammatory diseases.Fundamental research · 2024Review
- A biobehavioural and social-structural model of inflammation and executive function in pediatric chronic health conditions.Health psychology review · 2024Article
- Alzheimer's Disease Puzzle: Delving into Pathogenesis Hypotheses.Aging and disease · 2024Review
- Analysis of factors related to cognitive impairment in a community-based, complete enumeration survey in Japan: the Nakayama study.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2023Article
- Dementia Is Induced via the AGEs/Iba1/iNOS Pathway in Aged KK-Ay/Tajcl Mice.Life (Basel, Switzerland) · 2023Article
- Identification of a Link between Suspected Metabolic Syndrome and Cognitive Impairment within Pharmaceutical Care in Adults over 75 Years of Age.Healthcare (Basel, Switzerland) · 2023Article
- Pathophysiology of cognitive dysfunction and the role of combined brain/heart magnetic resonance imaging (Review).Experimental and therapeutic medicine · 2022Review
- Limb Remote Ischemic Conditioning Ameliorates Cognitive Impairment in Rats with Chronic Cerebral Hypoperfusion by Regulating Glucose Transport.Aging and disease · 2021Article
- Interaction betweenAlzheimer's & dementia (Amsterdam, Netherlands) · 2020Article
- Mechanisms Associated with Type 2 Diabetes as a Risk Factor for Alzheimer-Related Pathology.Molecular neurobiology · 2019Article
- Simultaneous in vivo optical quantification of key metabolic and vascular endpoints reveals tumor metabolic diversity in murine breast tumor models.Journal of biophotonics · 2019Article
- Peripheral transcriptomic biomarkers for early detection of sporadic Alzheimer disease?Dialogues in clinical neuroscience · 2018Review
- Environmental and Dietary Exposure to Copper and Its Cellular Mechanisms Linking to Alzheimer's Disease.Toxicological sciences : an official journal of the Society of Toxicology · 2018Review
- Systemic inflammation as a predictor of brain aging: Contributions of physical activity, metabolic risk, and genetic risk.NeuroImage · 2018Observational
- Chronic Cerebral Hypoperfusion Induced Synaptic Proteome Changes in the rat Cerebral Cortex.Molecular neurobiology · 2018Article
- Cerebrovascular-Reactivity Mapping Using MRI: Considerations for Alzheimer's Disease.Frontiers in aging neuroscience · 2018Article
- Metaflammasome components in the human brain: a role in dementia with Alzheimer's pathology?Brain pathology (Zurich, Switzerland) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well known that a specific set of genetic and non-genetic risk factors contributes to the onset of Alzheimer disease (AD). Non-genetic risk factors include diabetes, hypertension in mid-life, and probably dyslipidemia in mid-life. This review focuses on the vascular and metabolic components of non-genetic risk factors. The mechanisms whereby non-genetic risk factors modify cognitive dysfunction are divided into four components, short- and long-term effects of vascular and metabolic factors. These consist of (1) compromised vascular reactivity, (2) vascular lesions, (3) hypo/hyperglycemia, and (4) exacerbated AD histopathological features, respectively. Vascular factors compromise cerebrovascular reactivity in response to neuronal activity and also cause irreversible vascular lesions. On the other hand, representative short-term effects of metabolic factors on cognitive dysfunction occur due to hypoglycemia or hyperglycemia. Non-genetic risk factors also modify the pathological manifestations of AD in the long-term. Therefore, vascular and metabolic factors contribute to aggravation of cognitive dysfunction in AD through short-term and long-term effects. β-amyloid could be involved in both vascular and metabolic components. It might be beneficial to support treatment in AD patients by appropriate therapeutic management of non-genetic risk factors, considering the contributions of these four elements to the manifestation of cognitive dysfunction in individual patients, though all components are not always present. It should be clarified how these four components interact with each other. To answer this question, a clinical prospective study that follows up clinical features with respect to these four components: (1) functional MRI or SPECT for cerebrovascular reactivity, (2) MRI for ischemic lesions and atrophy, (3) clinical episodes of hypoglycemia and hyperglycemia, (4) amyloid-PET and tau-PET for pathological features of AD, would be required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.